Not applicableLooking for participantsNCT07064330
What this trial is testing
Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.
Who this might be right for
Cutaneous Squamous Cell Carcinoma (CSCC)
Instituto de Investigación Biomédica de Salamanca 30